Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · Chief Executive Officer | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,050,249 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 27 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 27 F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 213,250 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 213,250 F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 71,644 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 71,644 F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 26, 2024 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,821 | $46.34 | $130,737.27 |
DisclosureSEC source: 0001610717-24-000092 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 847,560 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:20 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $49.43 | $84,032.02 |
DisclosureSEC source: 0001610717-24-000071 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 850,381 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.10 to $49.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:20 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,300 | $48.58 | $160,300.14 |
DisclosureSEC source: 0001610717-24-000071 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 852,081 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.08 to $49.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:56 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $49.53 | $49,530.10 |
DisclosureSEC source: 0001610717-24-000058 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 855,381 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.50 to $49.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,035 | $45.65 | $47,244.33 |
DisclosureSEC source: 0001610717-24-000030 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 856,381 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.49 to $45.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,965 | $45.10 | $133,711.72 |
DisclosureSEC source: 0001610717-24-000030 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 857,416 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.48 to $45.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:17 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 14,935 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001610717-23-000426 · form4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,463 Underlying: Class A Common Stock · 14,935 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option, originally for 300,000 shares, of which 220,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021. F6 · balance_after: The balance for this grant has been updated from the filing made on December 28, 2021 to reflect the correct amount. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:17 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 14,935 | $1.20 | $17,922.00 |
DisclosureSEC source: 0001610717-23-000426 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 860,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $55.15 | $93,749.05 |
DisclosureSEC source: 0001610717-23-000402 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 845,446 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $54.73 to $55.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $54.39 | $16,316.01 |
DisclosureSEC source: 0001610717-23-000402 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 847,146 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.715 to $54.555. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 23:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,723 | $43.72 | $162,750.95 |
DisclosureSEC source: 0001610717-23-000364 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 847,446 F2 · price: This transaction was executed in multiple trades at prices ranging from $43.65 to $43.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 23:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,757 | $43.34 | $162,815.98 |
DisclosureSEC source: 0001610717-23-000364 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 851,169 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $39.52 | $79,040.60 |
DisclosureSEC source: 0001610717-23-000358 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 854,926 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.50 to $39.575. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 20:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,979 | $39.51 | $78,187.12 |
DisclosureSEC source: 0001610717-23-000312 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 856,926 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.50 to $39.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 21 | $39.50 | $829.50 |
DisclosureSEC source: 0001610717-23-000312 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 858,905 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 3,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000280 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 858,926 Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 80 | $49.82 | $3,985.60 |
DisclosureSEC source: 0001610717-23-000280 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 862,093 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.78 to $49.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,920 | $49.35 | $94,753.73 |
DisclosureSEC source: 0001610717-23-000280 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 862,173 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.78 to $49.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,757 | $45.78 | $171,999.59 |
DisclosureSEC source: 0001610717-23-000238 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 864,093 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 17 | $50.42 | $857.14 |
DisclosureSEC source: 0001610717-23-000228 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 867,850 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,983 | $50.10 | $99,354.84 |
DisclosureSEC source: 0001610717-23-000228 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 867,867 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 20,845 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001610717-23-000215 · form4.xml · derivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,478 Underlying: Class A Common Stock · 20,845 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 40,000 | $60.03 | $2,401,088.00 |
DisclosureSEC source: 0001610717-23-000215 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 869,850 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 20,845 | $5.04 | $105,058.80 |
DisclosureSEC source: 0001610717-23-000215 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 909,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 22:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,149 | $58.37 | $67,064.14 |
DisclosureSEC source: 0001610717-23-000205 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 889,005 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.02 to $58.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 22:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 851 | $57.61 | $49,026.28 |
DisclosureSEC source: 0001610717-23-000205 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 890,154 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.02 to $58.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 51 | $59.15 | $3,016.65 |
DisclosureSEC source: 0001610717-23-000171 · form4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,005 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.05 to $59.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,209 | $58.53 | $70,758.18 |
DisclosureSEC source: 0001610717-23-000171 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,056 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.05 to $59.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 740 | $57.50 | $42,552.81 |
DisclosureSEC source: 0001610717-23-000171 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 892,265 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.03 to $58.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 185 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000171 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 893,005 Read SEC document |
| May 23, 2023 Filed May 23, 2023 23:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,068 | $55.06 | $113,866.77 |
DisclosureSEC source: 0001610717-23-000062 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893,190 F2 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 23, 2023 Filed May 23, 2023 23:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 534 | $55.06 | $29,404.18 |
DisclosureSEC source: 0001610717-23-000062 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 895,258 F2 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 19, 2023 Filed May 23, 2023 23:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 460 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000062 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 27 F1 · ownership.nature: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,506 | $53.57 | $80,669.19 |
DisclosureSEC source: 0001610717-23-000045 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 895,792 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $53.08 to $53.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 494 | $52.70 | $26,032.37 |
DisclosureSEC source: 0001610717-23-000045 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 897,298 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $52.05 to $53.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 76 | $55.28 | $4,201.27 |
DisclosureSEC source: 0001610717-23-000013 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 897,792 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $55.15 to $55.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 283 | $54.64 | $15,462.19 |
DisclosureSEC source: 0001610717-23-000013 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 897,868 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $54.13 to $55.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,641 | $53.61 | $87,976.47 |
DisclosureSEC source: 0001610717-23-000013 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 898,151 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.12 to $54.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantPerformance - based Restricted Stock Units · Derivative | 72,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-013506 · form4.xml · derivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,773 Underlying: Class A Common Stock · 72,773 shares Expires 2028-04-01 F7 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs shall vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. F7 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs shall vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 72,773 | $0.00 Strike: $50.10 | $0.00 |
DisclosureSEC source: 0001140361-23-013506 · form4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,773 Underlying: Class A Common Stock · 72,773 shares Expires 2033-03-21 F6 · derivative.exercise_date: 1/48th of the total number of shares subject to the option vest on each monthly anniversary measured from April 1, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 22:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 36,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-013506 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,792 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:27 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 303 | $49.28 | $14,932.08 |
DisclosureSEC source: 0001567619-23-005183 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 863,405 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $49.15 to $49.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:27 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,697 | $48.81 | $82,823.78 |
DisclosureSEC source: 0001567619-23-005183 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 863,708 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.15 to $49.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Excludes 870 shares transferred to Sirius Trust, 6,050 shares transferred to Y/S Pot Trust and 37,390 shares transferred to the Y/S Descendants' Trust, on March 11, 2023. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 260 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004744 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 487 F1 · ownership.nature: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,941 | $47.75 | $92,689.16 |
DisclosureSEC source: 0001567619-23-003779 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,715 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 21:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-021571 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 747 F2 · ownership.nature: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001567619-22-021571 · doc1.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,035 Underlying: Class A Common Stock · 3,000 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option, originally for 300,000 shares, of which 261,965 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,000 | $1.20 | $3,600.00 |
DisclosureSEC source: 0001567619-22-021571 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Excludes 870 shares transferred to Sirius Trust, 9,400 shares transferred to Y/S Pot Trust and 56,000 shares transferred to the Y/S Descendants' Trust, on December 13, 2022. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,887 | $34.07 | $64,281.22 |
DisclosureSEC source: 0001567619-22-020871 · doc1.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,926 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 789 | $34.06 | $26,877.21 |
DisclosureSEC source: 0001567619-22-020871 · doc1.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,813 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.